Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mRNA COVID-19 vaccine + quadrivalent inactivated influenza vaccine
- Development stage
- Unknown
- Lead developer
- Duke Human Vaccine Institute
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
This refers to the co-administration of a quadrivalent inactivated influenza vaccine (IIV4) and an mRNA COVID-19 vaccine, currently being evaluated in a Phase 4 clinical trial led by Duke University (NCT06503900). The study specifically investigates the safety and immunogenicity of simultaneous versus sequential administration in pregnant women. The IIV4 component is a standard seasonal vaccine containing hemagglutinin antigens from four influenza strains: two influenza A subtypes (H1N1 and H3N2) and two influenza B lineages (Victoria and Yamagata). The mRNA COVID-19 vaccine component (such as those developed by Pfizer-BioNTech or Moderna) encodes the SARS-CoV-2 spike protein to elicit a protective immune response. The trial aims to optimize vaccination schedules for pregnant populations to ensure protection against both seasonal influenza and COVID-19 while monitoring local and systemic reactogenicity and placental antibody transfer.
- Other names
- IIV4 + mRNA COVID-19 vaccineSimultaneous mRNA COVID-19 and Influenza Vaccines in Pregnant Women
02
Targets
HA (Hemagglutinin)SARS-CoV-2 spike
Beyond the preview
Go deeper on mRNA COVID-19 vaccine + quadrivalent inactivated influenza vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mRNA COVID-19 vaccine + quadrivalent inactivated influenza vaccine.